GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Research & Development

Radiopharm Theranostics (ASX:RAD) Research & Development : A$17.56 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Radiopharm Theranostics's Research & Development for the six months ended in Dec. 2023 was A$15.10 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$17.56 Mil.

Radiopharm Theranostics Research & Development Historical Data

The historical data trend for Radiopharm Theranostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Research & Development Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24
Research & Development
4.13 13.80 17.56

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial 1.39 9.44 4.36 15.10 2.46

Radiopharm Theranostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$17.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics  (ASX:RAD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Radiopharm Theranostics Research & Development Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Research & Development
Comparable Companies
ASX:NOX ASX:AGN ASX:EZZ ASX:PAA ASX:BIO ASX:CYP ASX:1AI ASX:ACW ASX:BTC ASX:IXC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Website
https://www.radiopharmtheranostics.com
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics Headlines

No Headlines